Alto Neuroscience (ANRO) Change in Account Payables (2023 - 2026)

Alto Neuroscience has disclosed Change in Account Payables across 4 years of filings, most recently posting $1.5 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.5 million, up 660.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 327.24% YoY), and the FY2025 annual result was $221000.0, down 57.17% from the prior year.
• Change in Account Payables came in at $1.5 million for Q1 2026 at Alto Neuroscience, up from -$297000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q1 2026 to a low of -$781000.0 in Q4 2023.
• The 4-year median for Change in Account Payables is -$251000.0 (2024), against an average of $122692.3.
• Across the five-year window, Change in Account Payables sank 123.75% in 2025 and jumped 660.15% in 2026, its largest moves.
• Alto Neuroscience's Change in Account Payables stood at -$781000.0 in 2023, then advanced by 2.43% to -$762000.0 in 2024, then soared by 61.02% to -$297000.0 in 2025, then jumped by 601.68% to $1.5 million in 2026.
• The last three Change in Account Payables figures came in at $1.5 million (Q1 2026), -$297000.0 (Q4 2025), and $461000.0 (Q3 2025), per Business Quant data.